Health
Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients – News-Medical.Net
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), acco…
Reviewed by Emily Henderson, B.Sc.Oct 1 2020
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), according to a new study led by Yale Cancer Center (YCC) researchers.
The findings, from a global randomized phase 3 clinical trial published today in the New England Journal of Medicine, support the U.S. Food and Drug Administration’s approval of the drug for this indication in May.
These are e…
-
Noosa News23 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business21 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Noosa News19 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland
-
Noosa News21 hours ago150 jobs in doubt as Bega winds down peanut processing plants in Queensland